Life Sciences Center, Consortium Announce Research Funding
The Massachusetts Life Sciences Center (MLSC) and the Massachusetts Neuroscience Consortium announced the first round of awards to fund research on neurological diseases since the consortium launched in 2012.
The consortium, which includes Marlborough-based Sunovion Pharmaceuticals, Abbvie and Biogen Idec, which have operations in Worcester, as well as EMD Serono, Merck, Janssen Research and Development LLC, and Pfizer, reviewed applications from researchers at Massachusetts academic and research institutions and selected seven projects to receive a total of $1.75 million in funding, MLSC said.
The winning applicants include researchers from Boston University School of Medicine, Massachusetts General Hospital, the Massachusetts Alzheimer Disease Research Center, Brigham and Women's Hospital, Boston Children's Hospital, and the Massachusetts Institute of Technology.
Researchers will each receive $250,000 to study neurological diseases, including Alzheimer's disease, Multiple Sclerosis, neuropathic pain and Parkinson's disease. Each consortium member will act as a liaison to a corresponding project. Sunovion will fund Multiple Sclerosis research at Brigham and Women's; AbbVie will fund neuropathic pain research at Boston Children's Hospital and Biogen Idec will fund Alzheimer's research at Boston University School of Medicine.
"We are excited that the first solicitation yielded such a positive response from the state's academic and research institutions. We look forward to seeing the results of this research, and the impact it will have on patients suffering from the effects of Alzheimer's disease, Multiple Sclerosis, neuropathic pain and Parkinson's disease," MLSC President Susan Windham-Bannister said in a statement.
Read more
WBJ Web Partners
Most Recent
Most Recent
0 Comments